Intervacc AB (publ) (IVACC.ST)
SEK 2.38
(4.39%)
SEK 2.38
(4.39%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.01 Million SEK | -17.23% |
| 2022 | 9.68 Million SEK | 84.77% |
| 2021 | 5.24 Million SEK | 9.64% |
| 2020 | 4.78 Million SEK | -60.62% |
| 2019 | 12.13 Million SEK | -65.9% |
| 2018 | 35.6 Million SEK | -25.84% |
| 2017 | 48 Million SEK | -13.62% |
| 2016 | 55.57 Million SEK | -11.55% |
| 2015 | 62.83 Million SEK | -19.54% |
| 2014 | 78.08 Million SEK | 9729.64% |
| 2013 | 794.4 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.73 Million SEK | 14.24% |
| 2024 Q1 | 2.39 Million SEK | 47.23% |
| 2023 Q1 | 1.48 Million SEK | -61.82% |
| 2023 Q3 | 3.02 Million SEK | 60.68% |
| 2023 Q4 | 1.62 Million SEK | -46.23% |
| 2023 FY | 8.01 Million SEK | -17.23% |
| 2023 Q2 | 1.88 Million SEK | 26.9% |
| 2022 FY | 9.68 Million SEK | 84.77% |
| 2022 Q2 | 2.61 Million SEK | 122.87% |
| 2022 Q1 | 1.17 Million SEK | 9.74% |
| 2022 Q4 | 3.88 Million SEK | 92.66% |
| 2022 Q3 | 2.01 Million SEK | -22.82% |
| 2021 Q2 | 1.78 Million SEK | 60.13% |
| 2021 Q4 | 1.06 Million SEK | -15.91% |
| 2021 FY | 5.24 Million SEK | 9.64% |
| 2021 Q1 | 1.11 Million SEK | 18.35% |
| 2021 Q3 | 1.27 Million SEK | -28.93% |
| 2020 Q3 | 1.17 Million SEK | -25.46% |
| 2020 FY | 4.78 Million SEK | -60.62% |
| 2020 Q2 | 1.57 Million SEK | 43.47% |
| 2020 Q4 | 943 Thousand SEK | -19.47% |
| 2020 Q1 | 1.09 Million SEK | 1.48% |
| 2019 Q4 | 1.07 Million SEK | -48.13% |
| 2019 Q2 | 2.51 Million SEK | -61.21% |
| 2019 Q1 | 6.47 Million SEK | 102.63% |
| 2019 FY | 12.13 Million SEK | -65.9% |
| 2019 Q3 | 2.08 Million SEK | -17.13% |
| 2018 Q2 | 17.66 Million SEK | 368.6% |
| 2018 FY | 35.6 Million SEK | -25.84% |
| 2018 Q4 | 3.19 Million SEK | -70.91% |
| 2018 Q3 | 10.97 Million SEK | -37.87% |
| 2018 Q1 | 3.76 Million SEK | 23.54% |
| 2017 Q4 | 3.05 Million SEK | -72.45% |
| 2017 Q2 | 22.57 Million SEK | 99.72% |
| 2017 FY | 48 Million SEK | -13.62% |
| 2017 Q1 | 11.3 Million SEK | 139.78% |
| 2017 Q3 | 11.07 Million SEK | -50.95% |
| 2016 Q2 | 29.5 Million SEK | 380.19% |
| 2016 Q4 | 4.71 Million SEK | -69.01% |
| 2016 FY | 55.57 Million SEK | -11.55% |
| 2016 Q3 | 15.2 Million SEK | -48.45% |
| 2016 Q1 | 6.14 Million SEK | 0.0% |
| 2015 FY | 62.83 Million SEK | -19.54% |
| 2014 FY | 78.08 Million SEK | 9729.64% |
| 2013 FY | 794.4 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 86.206% |
| Ziccum AB (publ) | 3.74 Million SEK | -113.904% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 98.699% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 84.124% |
| Mendus AB (publ) | 28.48 Million SEK | 71.864% |
| Genovis AB (publ.) | 158.23 Million SEK | 94.935% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -83.242% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 95.297% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 81.741% |
| Aptahem AB (publ) | 2.63 Million SEK | -204.678% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -674.396% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -10309.091% |
| Fluicell AB (publ) | 3.33 Million SEK | -140.114% |
| Saniona AB (publ) | 16.84 Million SEK | 52.405% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 51.149% |
| Biovica International AB (publ) | 7.29 Million SEK | -9.945% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -566.251% |
| AcouSort AB (publ) | 10.55 Million SEK | 24.036% |
| Xintela AB (publ) | 78 Thousand SEK | -10175.641% |
| Abliva AB (publ) | 137 Thousand SEK | -5750.365% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 86.085% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -297.964% |
| OncoZenge AB (publ) | 3000.00 SEK | -267066.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -5070.968% |
| CombiGene AB (publ) | 5.54 Million SEK | -44.568% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.336% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.533% |
| Corline Biomedical AB | 25.03 Million SEK | 67.978% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -41.159% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -1011.65% |
| I-Tech AB | 120.86 Million SEK | 93.368% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 94.023% |
| Cyxone AB (publ) | 5.14 Million SEK | -55.692% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -13.688% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 24.846% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 28.629% |
| Nanologica AB (publ) | 1.44 Million SEK | -455.44% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -15022.642% |
| BioInvent International AB (publ) | 71.46 Million SEK | 88.784% |
| Alzinova AB (publ) | 270 Thousand SEK | -2868.519% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 77.243% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -447.839% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -184.018% |
| Simris Alg AB (publ) | 4.35 Million SEK | -84.084% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -6065.385% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 96.643% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -34747.826% |